ASX, BIOTECHS UP:LIVING CELL UP 10%; POLARTECHNICS DOWN 12.5%
January 25th 2007 07:01
Biotech Daily Market Report
Thursday January 25, 2007
THE MARKET
Fifteen of the Biotech Daily Top 40 stocks were up, 13 stocks fell and 12 traded unchanged.
Living Cell was best climbing two cents or 10.0 percent to 22 cents on moderate volumes, with Evogenix up 3.5 cents or 4.58 percent to 80 cents on small volumes.
Polatechnics led the falls for the second day in a row, down 4.5 cents or 12.5 percent to 31.5 cents on moderate volumes followed by Neuren down four cents or 8.08 percent to 45.5 cents.
TODAY’S NEWS
* ANTISENSE DOSES FIRST PHASE IIa MS PATIENT
* VISIOMED WINS US PATENT FOR ADAPTABLE SPACER
* PFIZER ASKS IDT TO GEAR-UP FOR PHASE III ANTIBIOTIC
* COGSTATE H1 REVENUE UP 43% TO $1.2m
* CIRCADIAN REDUCES IN AVEXA, SAYS SHARES WORTH $2.66
To view these articles readers need to subscribe to Biotech Daily.
See details at www.biotechdaily.com.au
Thursday January 25, 2007
ASX, BIOTECHS UP:
LIVING CELL UP 10%; POLARTECHNICS DOWN 12.5%
LIVING CELL UP 10%; POLARTECHNICS DOWN 12.5%
THE MARKET
Fifteen of the Biotech Daily Top 40 stocks were up, 13 stocks fell and 12 traded unchanged.
Living Cell was best climbing two cents or 10.0 percent to 22 cents on moderate volumes, with Evogenix up 3.5 cents or 4.58 percent to 80 cents on small volumes.
Polatechnics led the falls for the second day in a row, down 4.5 cents or 12.5 percent to 31.5 cents on moderate volumes followed by Neuren down four cents or 8.08 percent to 45.5 cents.
TODAY’S NEWS
* ANTISENSE DOSES FIRST PHASE IIa MS PATIENT
* VISIOMED WINS US PATENT FOR ADAPTABLE SPACER
* PFIZER ASKS IDT TO GEAR-UP FOR PHASE III ANTIBIOTIC
* COGSTATE H1 REVENUE UP 43% TO $1.2m
* CIRCADIAN REDUCES IN AVEXA, SAYS SHARES WORTH $2.66
To view these articles readers need to subscribe to Biotech Daily.
See details at www.biotechdaily.com.au
| 31 |
| Vote |
Add To: 
subscribe to this blog